Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Calcitriol in the treatment of prostate cancer.

Beer TM, Myrthue A.

Anticancer Res. 2006 Jul-Aug;26(4A):2647-51. Review.

2.

Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.

Beer TM, Myrthue A, Eilers KM.

World J Urol. 2005 Feb;23(1):28-32. Review.

PMID:
15668801
3.

Calcitriol in cancer treatment: from the lab to the clinic.

Beer TM, Myrthue A.

Mol Cancer Ther. 2004 Mar;3(3):373-81. Review.

4.

Development of weekly high-dose calcitriol based therapy for prostate cancer.

Beer TM.

Urol Oncol. 2003 Sep-Oct;21(5):399-405. Review.

PMID:
14670552
5.

Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.

Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD.

Semin Oncol. 2001 Aug;28(4 Suppl 15):49-55.

PMID:
11685729
6.

Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer.

Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL.

Clin Cancer Res. 2005 Nov 1;11(21):7794-9.

7.

Vitamin D compounds: clinical development as cancer therapy and prevention agents.

Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS.

Anticancer Res. 2006 Jul-Aug;26(4A):2551-6.

9.

Vitamin D receptor: a potential target for intervention.

Johnson CS, Hershberger PA, Bernardi RJ, Mcguire TF, Trump DL.

Urology. 2002 Sep;60(3 Suppl 1):123-30; discussion 130-1. Review.

PMID:
12231068
10.

Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.

Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL.

Cancer Chemother Pharmacol. 2007 Apr;59(5):581-7.

PMID:
17066293
11.
12.

Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.

Peehl DM, Seto E, Feldman D.

Urology. 2001 Aug;58(2 Suppl 1):123-6. Review.

PMID:
11502466
13.

Satraplatin: BMS 182751, BMY 45594, JM 216.

[No authors listed]

Drugs R D. 2007;8(2):125-32. Review.

PMID:
17324011
14.

A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.

Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL.

Clin Cancer Res. 1999 Jun;5(6):1339-45.

15.

Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation.

Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL.

Cancer Chemother Pharmacol. 2005 Nov;56(5):492-6.

PMID:
15918041
16.

RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.

Yin Y, Ni J, Chen M, Guo Y, Yeh S.

Clin Cancer Res. 2009 Jan 1;15(1):190-200. doi: 10.1158/1078-0432.CCR-08-0910.

17.

Anti-tumor activity of calcitriol: pre-clinical and clinical studies.

Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS.

J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):519-26. Review.

PMID:
15225831
18.

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.

Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW.

BJU Int. 2008 Dec;102(11):1601-6. doi: 10.1111/j.1464-410X.2008.08017.x.

19.
20.

Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.

Lin CC, Hsu CH, Hour TC, Cheng AL, Huang CY, Huang KH, Chen J, Pu YS.

Urol Oncol. 2007 May-Jun;25(3):207-13.

PMID:
17483017

Supplemental Content

Support Center